

=> file caplus; d que 19; d que 110  
 FILE 'CAPLUS' ENTERED AT 16:52:29 ON 19 SEP 2005  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Sep 2005 VOL 143 ISS 13  
 FILE LAST UPDATED: 18 Sep 2005 (20050918/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

L2	206557	SEA FILE=CAPLUS ABB=ON	PLU=ON	ANTITUMOR? OR ANTINEOPLAS? OR ANTICARCINO? OR ANTICANCER? OR CARCINOSTAT? OR ONCOLY?
L3	666615	SEA FILE=CAPLUS ABB=ON	PLU=ON	TUMOR? OR TUMOUR? OR CANCER? OR NEOPLAS? OR TUMOUR? (2A) (ANTI OR INHIBIT? OR THERAP? OR TREAT? OR SUPPRESS?)
L4	15958	SEA FILE=CAPLUS ABB=ON	PLU=ON	ANGIOGENESIS/CT OR NEOVASCULARIZATION/CW
L5	7764	SEA FILE=CAPLUS ABB=ON	PLU=ON	ANGIOGENESIS INHIBITORS/CT OR ANTIANGIOGENIC?
L6	6	SEA FILE=CAPLUS ABB=ON	PLU=ON	VCIP OR COLLAGEN INDUCIBLE PROTEIN
L7	11	SEA FILE=CAPLUS ABB=ON	PLU=ON	PHOSPHATIDIC ACID PHOSPHATASE 2B OR PAP2B
L9	6	SEA FILE=CAPLUS ABB=ON	PLU=ON	(L2 OR L3 OR L4 OR L5) AND (L6 OR L7)
L6	6	SEA FILE=CAPLUS ABB=ON	PLU=ON	VCIP OR COLLAGEN INDUCIBLE PROTEIN
L7	11	SEA FILE=CAPLUS ABB=ON	PLU=ON	PHOSPHATIDIC ACID PHOSPHATASE 2B OR PAP2B
L8	24381	SEA FILE=CAPLUS ABB=ON	PLU=ON	INTEGRINS+OLD/CT
L10	5	SEA FILE=CAPLUS ABB=ON	PLU=ON	L8 AND (L6 OR L7)

=> s 19 or 110  
 L24 6 L9 OR L10

=> file medline; d que 114  
 FILE 'MEDLINE' ENTERED AT 16:52:51 ON 19 SEP 2005

FILE LAST UPDATED: 17 SEP 2005 (20050917/UP). FILE COVERS 1950 TO DATE.

On December 19, 2004, the 2005 MeSH terms were loaded.

The MEDLINE reload for 2005 is now available. For details enter HELP RLOAD at an arrow prompt (=>). See also:

<http://www.nlm.nih.gov/mesh/>  
[http://www.nlm.nih.gov/pubs/techbull/nd04/nd04\\_mesh.html](http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html)

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2005 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
L11      1 SEA FILE=MEDLINE ABB=ON  PLU=ON  VCIP OR COLLAGEN INDUCIBLE
          PROTEIN
L12      4 SEA FILE=MEDLINE ABB=ON  PLU=ON  PHOSPHATIDIC ACID PHOSPHATASE
          2B OR PAP2B
L13      4 SEA FILE=MEDLINE ABB=ON  PLU=ON  L11 OR L12
L14      1 SEA FILE=MEDLINE ABB=ON  PLU=ON  L13 AND (CELL CELL)/TI
```

=> file biosis; d que l18  
 FILE 'BIOSIS' ENTERED AT 16:53:01 ON 19 SEP 2005  
 Copyright (c) 2005 The Thomson Corporation

FILE COVERS 1969 TO DATE.  
 CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNS) PRESENT  
 FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 14 September 2005 (20050914/ED)

FILE RELOADED: 19 October 2003.

```
L15      2 SEA FILE=BIOSIS ABB=ON  PLU=ON  VCIP OR COLLAGEN INDUCIBLE
          PROTEIN
L16      5 SEA FILE=BIOSIS ABB=ON  PLU=ON  PHOSPHATIDIC ACID PHOSPHATASE
          2B OR PAP2B
L17      6 SEA FILE=BIOSIS ABB=ON  PLU=ON  (L15 OR L16)
L18      1 SEA FILE=BIOSIS ABB=ON  PLU=ON  L17 AND ANGIO?/TI
```

=> file embase; d que l21  
 FILE 'EMBASE' ENTERED AT 16:53:15 ON 19 SEP 2005  
 COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE COVERS 1974 TO 15 Sep 2005 (20050915/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

L19 2 SEA FILE=EMBASE ABB=ON PLU=ON VCIP OR COLLAGEN INDUCIBLE  
PROTEIN  
L20 4 SEA FILE=EMBASE ABB=ON PLU=ON PHOSPHATIDIC ACID PHOSPHATASE  
2B OR PAP2B  
L21 5 SEA FILE=EMBASE ABB=ON PLU=ON (L19 OR L20)

*Note: No new relevant citations were found in this file.*

=> file wpiX; d que l22; d que l23  
FILE 'WPIX' ENTERED AT 16:53:25 ON 19 SEP 2005  
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE LAST UPDATED: 15 SEP 2005 <20050915/UP>  
MOST RECENT DERWENT UPDATE: 200559 <200559/DW>  
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,  
PLEASE VISIT:  
[http://www.stn-international.de/training\\_center/patents/stn\\_guide.pdf](http://www.stn-international.de/training_center/patents/stn_guide.pdf) <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE  
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER  
GUIDES, PLEASE VISIT:  
<http://thomsonderwent.com/support/userguides/> <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT  
DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX  
FIRST VIEW - FILE WPIFV.  
FOR FURTHER DETAILS: <http://www.thomsonderwent.com/dwpifv> <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.  
PLEASE CHECK:  
<http://thomsonderwent.com/support/dwpieref/reftools/classification/code-revision/>  
FOR DETAILS. <<<

L22 2 SEA FILE=WPIX ABB=ON PLU=ON VCIP OR COLLAGEN INDUCIBLE  
PROTEIN

L23 0 SEA FILE=WPIX ABB=ON PLU=ON PHOSPHATIDIC ACID PHOSPHATASE 2B  
OR PAP2B

=> dup rem l14 l24 l18 l22  
FILE 'MEDLINE' ENTERED AT 16:54:03 ON 19 SEP 2005

FILE 'CAPLUS' ENTERED AT 16:54:03 ON 19 SEP 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:54:03 ON 19 SEP 2005  
Copyright (c) 2005 The Thomson Corporation

FILE 'WPIX' ENTERED AT 16:54:03 ON 19 SEP 2005  
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

PROCESSING COMPLETED FOR L14  
 PROCESSING COMPLETED FOR L24  
 PROCESSING COMPLETED FOR L18  
 PROCESSING COMPLETED FOR L22  
 L25 7 DUP REM L14 L24 L18 L22 (3 DUPLICATES REMOVED)  
 ANSWER '1' FROM FILE MEDLINE  
 ANSWERS '2-6' FROM FILE CAPLUS  
 ANSWER '7' FROM FILE BIOSIS

=> d ibib ed ab 125 1-7

L25 ANSWER 1 OF 7 MEDLINE on STN DUPLICATE 3  
 ACCESSION NUMBER: 2003203084 MEDLINE  
 DOCUMENT NUMBER: PubMed ID: 12660161  
 TITLE: Regulation of **cell-cell** interactions by  
**phosphatidic acid phosphatase**  
**2b/VCIP**.  
 AUTHOR: Humtsoe Joseph O; Feng Shu; Thakker Geeta D; Yang Jun; Hong  
 Jun; Wary Kishore K  
 CORPORATE SOURCE: Center for Extracellular Matrix Biology, Institute of  
 Biosciences and Technology, Texas Medical Center, 2121 W  
 Holcombe Blvd, Houston, TX 77030, USA.  
 SOURCE: EMBO journal, (2003 Apr 1) 22 (7) 1539-54.  
 Journal code: 8208664. ISSN: 0261-4189.  
 PUB. COUNTRY: England: United Kingdom  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 200305  
 ENTRY DATE: Entered STN: 20030502  
 Last Updated on STN: 20030515  
 Entered Medline: 20030514  
 ED Entered STN: 20030502  
 Last Updated on STN: 20030515  
 Entered Medline: 20030514  
 AB We identified vascular endothelial growth factor and type I  
**collagen inducible protein (VCIP)**,  
 also known as **phosphatidic acid phosphatase**  
**2b (PAP2b)**, in a functional assay of angiogenesis.  
**VCIP/PAP2b** exhibits an Arg-Gly-Asp (RGD) cell adhesion  
 sequence. Immunoprecipitation and fluorescence-activated cell sorting  
 analyses demonstrated that **VCIP**-RGD is exposed to the outside of  
 the cell surface. Retroviral transduction of **VCIP** induced cell  
 aggregation/cell-cell interactions, modestly increased p120 catenin  
 expression and promoted activation of the Fak, Akt and GSK3beta protein  
 kinases. Furthermore, expression of recombinant **VCIP** promoted  
 adhesion, spreading and tyrosine phosphorylation of Fak, Shc, Cas and  
 paxillin in endothelial cells. GST-**VCIP**-RGD, but not GST-  
**VCIP**-RGE, specifically interacted with a subset of integrins, and  
 these interactions were effectively blocked by anti-alpha(v)beta(3) and  
 anti-alpha(5)beta(1) integrin antibodies, and by **PAP2b/**  
**VCIP**-derived peptides. Interestingly, **PAP2b/**  
**VCIP** is expressed in close proximity to vascular endothelial  
 growth factor, von Willebrand factor and alpha(v)beta(3) integrin in tumor  
 vasculatures. These findings demonstrate an unexpected function of  
**PAP2b/VCIP**, and represent an important step towards  
 understanding the molecular mechanisms by which **PAP2b/**  
**VCIP**-induced cell-cell interactions regulate specific  
 intracellular signaling pathways.

L25 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2005:15782 CAPLUS  
 DOCUMENT NUMBER: 142:107374  
 TITLE: VEGF- and type I **collagen-inducible protein (VCIP)**, also known as **PAP2b**, VCIP-derived peptides, and uses for diagnosis and anti-angiogenic and anti-**cancer** therapy  
 INVENTOR(S): Wary, Kishore K.; Humtsoe, Joseph O.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 73 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005002904	A1	20050106	US 2004-812238	20040329
WO 2005041860	A2	20050512	WO 2004-US21365	20040702
WO 2005041860	A3	20050623		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-485164P P 20030703

ED Entered STN: 07 Jan 2005

AB The inventors identified vascular endothelial growth factor and type I **collagen inducible protein (VCIP)**, also known as **phosphatidic acid phosphatase 2b (PAP2b)**, in a functional assay of angiogenesis. Previously, **VCIP** was not known to function as an integrin ligand. The present invention discloses that **VCIP**-derived peptides and proteins act as integrin ligands. Expression of recombinant **VCIP** promoted adhesion, spreading and tyrosine phosphorylation of Fak, Shc, Cas and paxillin in endothelial cells. Since **VCIP**-derived peptides or proteins are capable of inhibiting specific cell-cell interactions, such inhibitors of cell-cell interactions would be useful for developing novel therapeutic approaches to treat diseases where these interactions have clear pathol. consequences. Protein and cDNA sequences for human **VCIP** as well as **VCIP**-derived peptides are provided. For example, **VCIP/PAP2b** can be a novel target for anti-angiogenic, anti-**cancer** and anti-metastatic therapy.

L25 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2004:857620 CAPLUS  
 DOCUMENT NUMBER: 141:325700  
 TITLE: Sequences of human VEGF and type I **collagen inducible protein (VCIP)**

and use as a target for anti-tumor therapy  
 INVENTOR(S): Wary, Kishore K.; Humtsoe, Joseph O.  
 PATENT ASSIGNEE(S): The Texase A & M University System, USA  
 SOURCE: PCT Int. Appl., 115 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087736	A2	20041014	WO 2004-US9476	20040329
WO 2004087736	A3	20050331		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2003-458164P P 20030327

ED Entered STN: 18 Oct 2004

AB Vascular endothelial growth factor and type I **collagen inducible protein** (VICP), also known as phosphatic acid phosphatase 2b (**PAP2b**), was identified in a functional assay of angiogenesis. Previously, **VCIP** was not known to function as an integrin ligand. The present invention discloses **VCIP**-derived peptides and proteins act as integrin ligands. Since **VCIP**-derived peptides or proteins are capable of inhibiting specific cell-cell interactions, such inhibitors of cell-cell interactions have clear pathol. consequences. For example, **VCIP/PAP2b** can be a novel target for anti-angiogenic, anti-cancer and anti-metastatic therapy.

L25 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:673420 CAPLUS

DOCUMENT NUMBER: 143:167623

TITLE: Expression profiles of endothelial cells in response to TNF- $\alpha$ , IL-1 $\beta$ , and IL-8, methods of assessing a tissue inflammatory response using the same, and diagnostic and therapeutic uses

INVENTOR(S): Smith, Steven Kevin; Charnock-Jones, David Stephen; Print, Cristin Gregor; Johnson, Nicola Anne

PATENT ASSIGNEE(S): Cambridge University Technical Services Limited, UK

SOURCE: PCT Int. Appl., 492 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005068655	A2	20050728	WO 2005-GB57	20050114

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

GB 2004-976

A 20040116

ED Entered STN: 29 Jul 2005

AB The invention provides methods of assessing a tissue inflammatory response, comprising making a quant. determination of the level of at least five

transcripts shown in transcriptome provided in the invention or proteins encoded thereby, in a sample; and comparing the abundance of said transcripts or proteins so determined with the level of said transcript obtained from a control sample. Methods for diagnosis of a condition with which a tissue inflammatory response is associated are also provided, as are gene chip arrays and protein based assays suitable for use in these methods. Assay methods for determining a modulator of a tissue inflammatory response or a condition associated therewith also form part of the invention. The gene expression was profiled in human umbilical vein endothelial cells (HUVEC) contacted with a mixture of TNF- $\alpha$ , interleukin-1 $\beta$ , and interleukin-8. In addition, expression in different endothelial cells types obtained from different parts of the body, namely HUVEC, human coronary artery endothelial cells (HCAEC) and human uterine microvascular endothelial cells (UtMVEC) were analyzed. It was found that many transcripts were consistently regulated by inflammatory signals in all three cell types.

L25 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:824055 CAPLUS

DOCUMENT NUMBER: 141:330185

TITLE: Gene expression profiling for diagnosis and treatment of angiogenesis-related disorders

INVENTOR(S): Gonda, Thomas John; Kremmidiotis, Gabriel

PATENT ASSIGNEE(S): Bionomics Limited, Australia

SOURCE: PCT Int. Appl., 148 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004085675	A1	20041007	WO 2004-AU383	20040326
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,			

SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,  
 TD, TG

PRIORITY APPLN. INFO.: AU 2003-901511 A 20030328  
 ED Entered STN: 08 Oct 2004  
 AB The present invention provides methods of gene expression profiling for  
 diagnosis and treatment of angiogenesis-related disorders. Diseases of  
 the invention include **cancer**, rheumatoid arthritis, diabetic  
 retinopathy, psoriasis, cardiovascular diseases such as atherosclerosis,  
 ischemic limb disease and coronary heart disease.  
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2004:975661 CAPLUS  
 DOCUMENT NUMBER: 142:53369  
 TITLE: Variability in the degree of expression of  
 phosphorylated I $\kappa$ B $\alpha$  in chronic lymphocytic  
 leukemia cases With nodal involvement  
 AUTHOR(S): Rodriguez, Antonia; Martinez, Nerea; Camacho,  
 Francisca I.; Ruiz-Ballesteros, Elena; Algara,  
 Patrocinio; Garcia, Juan-Fernando; Menarguez, Javier;  
 Alvaro, Tomas; Fresno, Manuel F.; Solano, Fernando;  
 Mollejo, Manuela; Martin, Carmen; Piris, Miguel A.  
 CORPORATE SOURCE: Molecular Pathology Program, Centro Nacional de  
 Investigaciones Oncologicas, Madrid, Spain  
 SOURCE: Clinical Cancer Research (2004), 10(20), 6796-6806  
 CODEN: CCREF4; ISSN: 1078-0432  
 PUBLISHER: American Association for Cancer Research  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 ED Entered STN: 16 Nov 2004  
 AB Based on previous preliminary observations, the authors hypothesize that  
 the mol. and clin. variability of chronic lymphocytic leukemia (CLL)  
 reflects differences in the degree of nuclear factor (NF)- $\kappa$ B  
 activation, as determined by the expression of phosphorylated I $\kappa$ B $\alpha$   
 (p-I $\kappa$ B $\alpha$ ). The expression profile (mRNA and protein  
 expression) was analyzed with the Centro Nacional de Investigaciones  
 Oncologicas Oncochip, a cDNA microarray containing 6386 **cancer**  
 -related genes, and a tissue microarray (TMA). The results were  
 correlated with the IgVH mutational status, ZAP-70 expression, cytogenetic  
 alterations, and clin. outcome. The authors found correlations between  
 the presence of p-I $\kappa$ B $\alpha$ , a surrogate marker of NF- $\kappa$ B  
 activation, and changes in the expression profile (mRNA and protein  
 expression) and clin. outcome in a series of CLL cases with lymph node  
 involvement. Activation of NF- $\kappa$ B, as determined by the expression of  
 p-I $\kappa$ B $\alpha$ , was associated with the expression of a set of genes  
 comprising key genes involved in the control of B-cell receptor signaling,  
 signal transduction, and apoptosis, including SYK, LYN, BCL2, CCR7, BTK,  
 PIK3CD, and others. Cases with increased expression of p-I $\kappa$ B $\alpha$   
 showed longer overall survival than cases with lower expression. A Cox  
 regression model was derived to estimate some parameters of prognostic  
 interest: IgVH mutational status, ZAP-70, and p-I $\kappa$ B $\alpha$   
 expression. The multivariate anal. disclosed p-I $\kappa$ B $\alpha$  and  
 ZAP-70 expression as independent prognostic factors of survival. A  
 variable degree of activation of NF- $\kappa$ B, as determined by the expression  
 of p-I $\kappa$ B $\alpha$ , is an identifiable event in CLL, and is correlated  
 with changes in the expression profile and overall survival.  
 REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L25 ANSWER 7 OF 7 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN  
 ACCESSION NUMBER: 2003:186580 BIOSIS  
 DOCUMENT NUMBER: PREV200300186580  
 TITLE: **VCIP** induces cell-cell interactions: Its role in **angiogenesis**.  
 AUTHOR(S): Wary, K. K. [Reprint Author]  
 CORPORATE SOURCE: Center for Extracellular Matrix Biology, Institute of  
 Biosciences and Technology, Houston, TX, USA  
 SOURCE: Molecular Biology of the Cell, (Nov 2002) Vol. 13, No.  
 Supplement, pp. 75a-76a. print.  
 Meeting Info.: 42nd Annual Meeting of the American Society  
 for Cell Biology. San Francisco, CA, USA. December 14-18,  
 2002. American Society for Cell Biology.  
 ISSN: 1059-1524 (ISSN print).  
 DOCUMENT TYPE: Conference; (Meeting)  
 Conference; Abstract; (Meeting Abstract)  
 LANGUAGE: English  
 ENTRY DATE: Entered STN: 16 Apr 2003  
 Last Updated on STN: 16 Apr 2003  
 ED Entered STN: 16 Apr 2003  
 Last Updated on STN: 16 Apr 2003

=> file home  
 FILE 'HOME' ENTERED AT 16:54:33 ON 19 SEP 2005

=&gt; d his full

(FILE 'HOME' ENTERED AT 16:08:55 ON 19 SEP 2005)

FILE 'CAPLUS' ENTERED AT 16:09:22 ON 19 SEP 2005

E US2004-812238/AP

L1 1 SEA ABB=ON PLU=ON US2004-812238/AP  
D IALL

FILE 'HOME' ENTERED AT 16:10:09 ON 19 SEP 2005

FILE 'ZCAPLUS' ENTERED AT 16:20:36 ON 19 SEP 2005

E INTEGRINS+ALL/CT

E ANTITUMOR AGENTS+NT/CT

E ANTITUMOR AGENTS+ALL/CT

E INTEGRIN+NT/CT

E E1

E E3

E E3+ALL

E E2+ALL

E ANGIOGENESIS+NT/CT

E ANTIANGIOGENE/CT

E E5+ALL

E E2+ALL

FILE 'REGISTRY' ENTERED AT 16:32:20 ON 19 SEP 2005

E VCIP/CN

E PAP2B/CN

E PHOSPHATIDIC ACID PHOSPHATASE 2B/CN

FILE 'CAPLUS' ENTERED AT 16:33:40 ON 19 SEP 2005

L2 206557 SEA ABB=ON PLU=ON ANTITUMOR? OR ANTINEOPLAS? OR ANTICARCINO?  
OR ANTICANCER? OR CARCINOSTAT? OR ONCOLY?

L3 666615 SEA ABB=ON PLU=ON TUMOR? OR TUMOUR? OR CANCER? OR NEOPLAS?  
OR TUMOUR? (2A) (ANTI OR INHIBIT? OR THERAP? OR TREAT? OR  
SUPPRESS?)

L4 15958 SEA ABB=ON PLU=ON ANGIOGENESIS/CT OR NEOVASCULARIZATION/CW

L5 7764 SEA ABB=ON PLU=ON ANGIOGENESIS INHIBITORS/CT OR ANTIANGIOGENI  
C?

L6 6 SEA ABB=ON PLU=ON VCIP OR COLLAGEN INDUCIBLE PROTEIN

L7 11 SEA ABB=ON PLU=ON PHOSPHATIDIC ACID PHOSPHATASE 2B OR PAP2B

L8 24381 SEA ABB=ON PLU=ON INTEGRINS+OLD/CT

L9 6 SEA ABB=ON PLU=ON (L2 OR L3 OR L4 OR L5) AND (L6 OR L7)

D SCAN TI

D SCAN

L\*\*\* DEL 14 S L6-L7

L\*\*\* DEL 8 S L10 NOT L9

D SCAN TI

L10 5 SEA ABB=ON PLU=ON L8 AND (L6 OR L7)

L\*\*\* DEL 0 S L10 NOT L9

FILE 'MEDLINE' ENTERED AT 16:44:14 ON 19 SEP 2005

L11 1 SEA ABB=ON PLU=ON VCIP OR COLLAGEN INDUCIBLE PROTEIN

L12 4 SEA ABB=ON PLU=ON PHOSPHATIDIC ACID PHOSPHATASE 2B OR PAP2B

L\*\*\* DEL 0 S L11L1L2

L13 4 SEA ABB=ON PLU=ON L11 OR L12

D TRIAL 1-4

L14 1 SEA ABB=ON PLU=ON L13 AND (CELL CELL)/TI

FILE 'BIOSIS' ENTERED AT 16:46:18 ON 19 SEP 2005

L15 2 SEA ABB=ON PLU=ON VCIP OR COLLAGEN INDUCIBLE PROTEIN  
 L16 5 SEA ABB=ON PLU=ON PHOSPHATIDIC ACID PHOSPHATASE 2B OR PAP2B  
 L17 6 SEA ABB=ON PLU=ON (L15 OR L16)  
 D SCAN  
 L18 1 SEA ABB=ON PLU=ON L17 AND ANGIO?/TI

FILE 'EMBASE' ENTERED AT 16:47:56 ON 19 SEP 2005

E VCIP/CT  
 E E4  
 E PAP2B/CT  
 E PHOSPHATIDIC ACID PHOSPHATASE/CT  
 L19 2 SEA ABB=ON PLU=ON VCIP OR COLLAGEN INDUCIBLE PROTEIN  
 L20 4 SEA ABB=ON PLU=ON PHOSPHATIDIC ACID PHOSPHATASE 2B OR PAP2B  
 L21 5 SEA ABB=ON PLU=ON (L19 OR L20)  
 D TRIAL 1-5

FILE 'WPIX' ENTERED AT 16:50:40 ON 19 SEP 2005

L22 2 SEA ABB=ON PLU=ON VCIP OR COLLAGEN INDUCIBLE PROTEIN  
 L23 0 SEA ABB=ON PLU=ON PHOSPHATIDIC ACID PHOSPHATASE 2B OR PAP2B  
 D SCAN L22

FILE 'CAPLUS' ENTERED AT 16:52:29 ON 19 SEP 2005

D QUE L9  
 D QUE L10  
 L24 6 SEA ABB=ON PLU=ON L9 OR L10

FILE 'MEDLINE' ENTERED AT 16:52:51 ON 19 SEP 2005

D QUE L14

FILE 'BIOSIS' ENTERED AT 16:53:01 ON 19 SEP 2005

D QUE L18

FILE 'EMBASE' ENTERED AT 16:53:15 ON 19 SEP 2005

D QUE L21

FILE 'WPIX' ENTERED AT 16:53:25 ON 19 SEP 2005

D QUE L22  
 D QUE L23

FILE 'MEDLINE, CAPLUS, BIOSIS, WPIX' ENTERED AT 16:54:03 ON 19 SEP 2005

L25 7 DUP REM L14 L24 L18 L22 (3 DUPLICATES REMOVED)  
 ANSWER '1' FROM FILE MEDLINE  
 ANSWERS '2-6' FROM FILE CAPLUS  
 ANSWER '7' FROM FILE BIOSIS  
 D IBIB ED AB L25 1-7

FILE 'HOME' ENTERED AT 16:54:33 ON 19 SEP 2005

FILE HOME

FILE CAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Sep 2005 VOL 143 ISS 13  
FILE LAST UPDATED: 18 Sep 2005 (20050918/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

#### FILE ZCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 19 Sep 2005 VOL 143 ISS 13  
FILE LAST UPDATED: 18 Sep 2005 (20050918/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

#### FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 SEP 2005 HIGHEST RN 863382-78-9  
DICTIONARY FILE UPDATES: 18 SEP 2005 HIGHEST RN 863382-78-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

FILE MEDLINE

FILE LAST UPDATED: 17 SEP 2005 (20050917/UP). FILE COVERS 1950 TO DATE.

On December 19, 2004, the 2005 MeSH terms were loaded.

The MEDLINE reload for 2005 is now available. For details enter HELP RLOAD at an arrow prompt (=>). See also:

<http://www.nlm.nih.gov/mesh/>  
[http://www.nlm.nih.gov/pubs/techbull/nd04/nd04\\_mesh.html](http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html)

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2005 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 14 September 2005 (20050914/ED)

FILE RELOADED: 19 October 2003.

FILE EMBASE

FILE COVERS 1974 TO 15 Sep 2005 (20050915/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE WPIX

FILE LAST UPDATED: 15 SEP 2005 <20050915/UP>  
MOST RECENT DERWENT UPDATE: 200559 <200559/DW>  
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,  
PLEASE VISIT:  
[http://www.stn-international.de/training\\_center/patents/stn\\_guide.pdf](http://www.stn-international.de/training_center/patents/stn_guide.pdf) <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE  
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER  
GUIDES, PLEASE VISIT:  
<http://thomsonderwent.com/support/userguides/> <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT

10/812,238 Haddad

DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX  
FIRST VIEW - FILE WPIFV.

FOR FURTHER DETAILS: <http://www.thomsonderwent.com/dwpifv> <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.  
PLEASE CHECK:

<http://thomsonderwent.com/support/dwpioref/reftools/classification/code-rev>  
FOR DETAILS. <<<

=>